In this study, we identified YTHDF2 as a prognostic factor for poor glioma patient survival and found that YTHDF2 overexpression in GBM cells is required for GBM cell growth, invasion, and tumor formation in vivo. This evidence concerns the gene YTHDF2 and glioblastoma.